Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
There is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chines...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2020/5289136 |
id |
doaj-4b201b81c058483a9d4d36957b9f36a5 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuyan Tan Weiguo Liu Juanjuan Du Miaomiao Hou Cuiyu Yu Yang Liu Shishuang Cui Lei Yan Yizhou Lu Hong Lv Lijun Han Xi Wang Shengyu Zha Xiaoguang Luo Huidong Tang Shengdi Chen |
spellingShingle |
Yuyan Tan Weiguo Liu Juanjuan Du Miaomiao Hou Cuiyu Yu Yang Liu Shishuang Cui Lei Yan Yizhou Lu Hong Lv Lijun Han Xi Wang Shengyu Zha Xiaoguang Luo Huidong Tang Shengdi Chen Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients Parkinson's Disease |
author_facet |
Yuyan Tan Weiguo Liu Juanjuan Du Miaomiao Hou Cuiyu Yu Yang Liu Shishuang Cui Lei Yan Yizhou Lu Hong Lv Lijun Han Xi Wang Shengyu Zha Xiaoguang Luo Huidong Tang Shengdi Chen |
author_sort |
Yuyan Tan |
title |
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients |
title_short |
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients |
title_full |
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients |
title_fullStr |
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients |
title_full_unstemmed |
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients |
title_sort |
validation of revised chinese version of pd-crs in parkinson’s disease patients |
publisher |
Hindawi Limited |
series |
Parkinson's Disease |
issn |
2090-8083 2042-0080 |
publishDate |
2020-01-01 |
description |
There is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chinese version of Parkinson’s disease-cognitive rating scale (PD-CRS), establish cutoff scores for diagnosis of Parkinson’s disease dementia (PDD) and PD with mild cognitive impairment (PD-MCI), explore cognitive profiles of PD-MCI and PDD, and find cognitive deficits suggesting a transition from PD-MCI to PDD. PD-CRS was revised based on the culture background of Chinese people. Ninety-two PD patients were recruited in three PD centers and were classified into PD with normal cognitive function (PD-NC), PD-MCI, and PDD subgroups according to the cognitive rating scale (CDR). Those PD patients underwent PD-CRS blind assessment by a separate neurologist. The PD-CRS showed a high internal consistency (Cronbach’s Alpha = 0.840). Intraclass Correlation coefficient (ICC) of test-retest reliability reached 0.906 (95% CI 0.860–0.935, p<0.001). ICC of inter-rater reliability was 0.899 (95% CI 0.848–0.933, p<0.001). PD-CRS had fair concurrent validity with MDRS (ICC = 0.731, 95% CI 0.602–0.816). All the frontal-subcortical items showed significant decrease in PD-MCI compared with the PD-NC group (p≤0.001), but the instrument cortical items did not (confrontation naming p=0.717, copying a clock p=0.620). All the frontal-subcortical and instrumental-cortical functions showed significant decline in PDD compared with the PD-NC group (p≤0.001). The cutoff value for diagnosis of PD-MCI is 80.5 with the sensitivity of 75.7% and the specificity of 75.0%, and for diagnosis of PDD is 73.5 with the sensitivity of 89.2% and the specificity of 98.9%. Revised Chinese version of PD-CRS is a reliable, acceptable, valid, and useful neuropsychological battery for assessing cognition in PD patients. |
url |
http://dx.doi.org/10.1155/2020/5289136 |
work_keys_str_mv |
AT yuyantan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT weiguoliu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT juanjuandu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT miaomiaohou validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT cuiyuyu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT yangliu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT shishuangcui validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT leiyan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT yizhoulu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT honglv validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT lijunhan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT xiwang validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT shengyuzha validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT xiaoguangluo validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT huidongtang validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients AT shengdichen validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients |
_version_ |
1715776738844213248 |
spelling |
doaj-4b201b81c058483a9d4d36957b9f36a52020-11-25T01:24:55ZengHindawi LimitedParkinson's Disease2090-80832042-00802020-01-01202010.1155/2020/52891365289136Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease PatientsYuyan Tan0Weiguo Liu1Juanjuan Du2Miaomiao Hou3Cuiyu Yu4Yang Liu5Shishuang Cui6Lei Yan7Yizhou Lu8Hong Lv9Lijun Han10Xi Wang11Shengyu Zha12Xiaoguang Luo13Huidong Tang14Shengdi Chen15Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology, Ruijin Hospital North Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201800, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaThere is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chinese version of Parkinson’s disease-cognitive rating scale (PD-CRS), establish cutoff scores for diagnosis of Parkinson’s disease dementia (PDD) and PD with mild cognitive impairment (PD-MCI), explore cognitive profiles of PD-MCI and PDD, and find cognitive deficits suggesting a transition from PD-MCI to PDD. PD-CRS was revised based on the culture background of Chinese people. Ninety-two PD patients were recruited in three PD centers and were classified into PD with normal cognitive function (PD-NC), PD-MCI, and PDD subgroups according to the cognitive rating scale (CDR). Those PD patients underwent PD-CRS blind assessment by a separate neurologist. The PD-CRS showed a high internal consistency (Cronbach’s Alpha = 0.840). Intraclass Correlation coefficient (ICC) of test-retest reliability reached 0.906 (95% CI 0.860–0.935, p<0.001). ICC of inter-rater reliability was 0.899 (95% CI 0.848–0.933, p<0.001). PD-CRS had fair concurrent validity with MDRS (ICC = 0.731, 95% CI 0.602–0.816). All the frontal-subcortical items showed significant decrease in PD-MCI compared with the PD-NC group (p≤0.001), but the instrument cortical items did not (confrontation naming p=0.717, copying a clock p=0.620). All the frontal-subcortical and instrumental-cortical functions showed significant decline in PDD compared with the PD-NC group (p≤0.001). The cutoff value for diagnosis of PD-MCI is 80.5 with the sensitivity of 75.7% and the specificity of 75.0%, and for diagnosis of PDD is 73.5 with the sensitivity of 89.2% and the specificity of 98.9%. Revised Chinese version of PD-CRS is a reliable, acceptable, valid, and useful neuropsychological battery for assessing cognition in PD patients.http://dx.doi.org/10.1155/2020/5289136 |